Compare GSK plc (GSK) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Intel Corp — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Intel Corp trades at $104.7 (market cap $566.04B). The key difference: Intel Corp is far larger — about 6.2× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Intel Corp for 116 Days on average.
| GSK | INTC | |
|---|---|---|
Market Cap | $91.88B | $566.04B |
Volume | 7,730,529 | 118,475,837 |
Sector | Health | Technology |
52-Week High | $61.18 | $140.94 |
52-Week Low | $43.24 | $33.62 |
Typical Hold Time | 93 Days | 116 Days |
Enterprise Value | $111.88B | $586.85B |
Dividend Yield | 3.9% | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Intel (INTC) trades at $107.08, down 5.34% over 24 hours, with a bullish technical breakout pattern despite near-term bearish momentum indicators. The company reported three consecutive quarterly EPS beats but posted a net loss of -$267 million in 2025, with revenue declining to $52.85 billion. Intel Foundry's 31% year-over-year growth in Q2 2026 and High-NA chipmaking progress highlight its strategic pivot, though profitability remains challenged with a negative net margin of -0.51%.
Intel's outlook balances a 222% stock surge in 2026 against high valuation multiples and persistent margin pressures. Investment opportunities lie in its foundry turnaround and AI infrastructure positioning, but risks include intense competition, execution challenges, and debt levels. Analyst consensus is cautious with a $111.72 price target and 54% hold ratings, signaling wait-and-see sentiment amid volatile fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
